From Wikipedia, the free encyclopedia
  (Redirected from Stribild)
Jump to: navigation, search
Bottle of Stribild with Dutch language writing next to green Stribild tablets.
Combination of
elvitegravir integrase inhibitor
cobicistat cytochrome P450 inhibitor
emtricitabine reverse-transcriptase inhibitor
tenofovir disoproxil fumarate reverse-transcriptase inhibitor
Clinical data
Trade names Stribild
AHFS/Drugs.com entry
  • US: B (No risk in non-human studies)
DrugBank http://www.drugbank.ca/drugs/DB00300

Elvitegravir/cobicistat/emtricitabine/tenofovir (brand name Stribild), also known as the Quad pill, is a fixed dose combination drug for the treatment of HIV/AIDS. Elvitegravir, emtricitabine and tenofovir directly suppress viral reproduction. Cobicistat increases the effectiveness of the combination by inhibiting the liver and gut wall enzymes that metabolize elvitegravir.

The drug is manufactured by Gilead Sciences. Stribild gained approval by U.S. Food and Drug Administration on August 27, 2012 for use in adult patients starting antiretroviral treatment for the first time as part of the fixed dose combination.